drugset / Trial / NCT06327295
A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis
Timeline
- Start
- 2024-07-01
- Primary completion
- 2025-06-30
- Completion
- 2026-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATB1651 | Unknown | 3 % | Topical |
| Subject | ATB1651 | Unknown | 5 % | Topical |